Release of the US Phase II Clinical Outcomes of Xuezhikangin Beijing
2013-02-05 09:25    

On January 11, "China Medicines' Innovation Strategy-International Seminar on Phase II Clinical Outcomes of Xuezhikang" which was co-organized by Chinese Pharmaceutical Association and LuyePharma Group was held in Beijing.At theseminar, Phase II clinical outcomes of Xuezhikang were grandly announced and innovative drug development and internationalization were also discussed.The meeting, chaired by Wang Guangji and the other two professors with Chinese Pharmaceutical Association, was attended by nearly 200 people including several academicians such as Sang Guowei, Chen Keji and Zhang Boli, related department heads, medical experts and media reporters.

Chairman Liu Dianbo, on behalf of LuyePharma Group, made the opening address.He thanked the leaders and experts for their great support for the research and development of Xuezhikangand LuyePharma Group over the years while declaring that LuyePharma Group will adhere to the road of independent innovation and internationalization and promising to make more contributionsto the innovative development of China's pharmaceuticals.

Chairman Liu Dianboismaking the opening address.
Academician Sang Guowei, Vice chairman of the Standing Committee of the National People's Congress, Chairman of the Chinese Pharmaceutical Association and Chief Technician of Major National New Drugs Creation Program, attended the seminar and made a report themed with "China'sResearch and Developmentin Innovative Drugs and GCP Principles for Clinical Trials". In his report, he introduced international lipid-lowering drugs and progress in cardiovascular clinical research as well as GCP standards for clinical trials.He also encouraged pharmaceutical companies in China to strengthen their capability of independent innovation, and actively develop more innovative drugs to going global.
Vice-chairman Sang Guowei is making a report.
Professor Marioty, a therapist of the University of Kansas who is also one of the major researchers of Phase II Clinical Outcomes of Xuezhikang in the US reported the research findings. His report points out that Xuezhikang can significantly lower low-density lipoprotein cholesterol in patients while elevating high-density lipoprotein cholesterol which is beneficial to human body and no significant adverse reactions were found. The success of this research has laid a solid foundation for Phase III clinical research of Xuezhikang in the US.Professor Zhao Shuiping, a cardiovascular specialist from the Second Xiangya Hospital of Central South University, reviewed the studies of Xuezhikang after its launch in the domestic market. Among all studies, a large-scale evidence-based research named "Study of Secondary Prevention of Coronary Heart Disease in China"proves that not only can Xuezhikang effectively regulate abnormal blood lipids but it can also significantly reduce cardiovascular events and total mortality.
Dr. DuanZhenwen, General Manager of Peking University Weixin Biological Technology under LuyePharma Group introduced theR & D course of Xuezhikang.Dr. Li Youxin, Vice President of the Group introduced R & D innovation, and international practice of the Group. Dr. Chen Shilin with China Academy of the Chinese Medical Sciences made a report on the progress of the traditional Chinese Medicinein innovative research.Finally, experts present at the seminar conducted a lively and active discussion.
Dr. DuanZhenwen is introducing the R & D course of Xuezhikang.
Dr. Zhao Shuiping is making a report.
Dr. Chen Shilinis making a report.
Dr. Li Youxin is introducingtheinnovation and international practice of the Group.
Professor Wang Guangji is chairing the seminar.
This international seminar was a great success, as it has made the whole society have a more extensive and in-depth understanding of the internationalized process of the traditional Chinese medicines represented by Xuezhikang and of the road of independent innovation of enterprises represented by LuyePharma Group, andhelped attract more attention and win recognition for the product and the Group. The seminar has also played an important role in further enhancing the brand influence of Xuezhikang and LuyePharma Group, and promoting the development of domestic and international marketsfor Xuezhikang.
On-site Interaction and Question-asking
distributed by